nach oben

Erschienen in:

09.01.2021 | Clinical Study

Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database

verfasst von: Takahisa Mikami, MD, Bobby Liaw, MD, Mizuho Asada, PhD, Takahiro Niimura, BS, Yoshito Zamami, PhD, Deborah Green-LaRoche, MD, Lori Pai, MD, Michael Levy, MD PhD, Suriya Jeyapalan, MD MPH

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the characteristics and risk factors for neurologic adverse events (AEs) induced by immune checkpoint inhibitors (ICIs).

Methods

An observational, retrospective, and pharmacovigilance study based on the FAERS database collected between January 2014 and December 2019 was conducted. ICI-related AEs were defined as adverse reactions in patients using anti-PD-1 (nivolumab and pembrolizumab), anti-PD-L1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA-4 (ipilimumab and tremelimumab). Neurologic AEs previously reported to be associated with ICI were evaluated in the disproportionality analysis using the reporting odds ratio (ROR).

Results

Among 50,406 ICI-related reports, 3619 (7.2%) neurological case was found: 1985 with anti-PD-1, 372 with anti-PD-L1, 366 with anti-CTLA-4, and 896 with the combination of ICIs. In comparison to non-ICI drug use, ICI use demonstrated higher risk for neurologic complication, including hypophysitis/hypopituitarism, myasthenia gravis, encephalitis/myelitis, meningitis, Guillain-Barre syndrome, vasculitis, and neuropathy. The risk of neurologic AEs associated with ICI combination therapy was as high as or even higher than ICI monotherapy, most significantly in hypophysitis/hypopituitarism. The proportion of serious neurological events and death related to combination therapy has been decreasing in recent years. Older age, male and female sex, and metastasis were not significant risk factors for the incidence of neurologic ICI-related AEs. Patients at older age, with melanoma or non-small cell lung cancer, or on dual ICI therapy may be at higher risk of fatal neurologic AEs.

Conclusion

ICI use is associated with a higher risk of neurological complications, with dual ICI therapy posing a higher risk, while older age, sex, or metastasis were not. Patients at older age, with certain cancer types, or on dual ICI therapy may be at higher risk of fatal neurologic AEs.

Nur mit Berechtigung zugänglich

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239CrossRefPubMedPubMedCentral

Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8. https://doi.org/10.1016/j.ejca.2016.12.001CrossRefPubMed

Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923CrossRefPubMedPubMedCentral

Larkin J, Chmielowski B, Lao CD et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22:709–718. https://doi.org/10.1634/theoncologist.2016-0487CrossRefPubMedPubMedCentral

Garcia CA, El-Ali A, Rath TJ et al (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6:1–6. https://doi.org/10.1186/s40425-018-0393-zCrossRef

Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:1–9. https://doi.org/10.1186/s40425-019-0617-xCrossRef

Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225. https://doi.org/10.1016/j.ejca.2016.02.024CrossRefPubMed

Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24:435–443. https://doi.org/10.1634/theoncologist.2018-0359CrossRefPubMed

Ji H-H, Tang XW, Dong Z et al (2019) Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig 39:319–330. https://doi.org/10.1007/s40261-018-0735-0CrossRefPubMed

10.

Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L et al (2018) Retrospective side effect profiling of the metastatic melanoma combination therapy ipilimumab-nivolumab using adverse event data. Diagnostics 8:76. https://doi.org/10.3390/diagnostics8040076CrossRefPubMedCentral

11.

US Food and Drug Administration (FDA) (2012) Code of federal regulations title 21. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32. Accessed 8 May 2020

12.

Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315–321. https://doi.org/10.1007/s002280050466CrossRefPubMed

13.

Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589. https://doi.org/10.1016/S1470-2045(18)30608-9CrossRefPubMedPubMedCentral

14.

Spain L, Walls G, Julve M et al (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28:377–385. https://doi.org/10.1093/annonc/mdw558CrossRefPubMed

15.

Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti–programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216–1222. https://doi.org/10.1001/jamaneurol.2017.1912CrossRefPubMedPubMedCentral

16.

Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 11

17.

Hassel JC, Heinzerling L, Aberle J et al (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003CrossRefPubMed

18.

Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neuro-Oncol 145:1–9. https://doi.org/10.1007/s11060-019-03273-1CrossRef

19.

Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127–1134. https://doi.org/10.1212/WNL.0000000000004359CrossRefPubMed

20.

Kennedy LC, Bhatia S, Thompson JA, Grivas P (2019) Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. JNCCN J Natl Compr Cancer Netw 17:750–757. https://doi.org/10.6004/jnccn.2019.7310CrossRef

21.

Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659–669. https://doi.org/10.1002/ana.25708CrossRefPubMed

22.

Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17:e529–e541. https://doi.org/10.1016/S1470-2045(16)30571-XCrossRefPubMed

23.

Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18:1–9. https://doi.org/10.1007/s11910-018-0878-7CrossRef

Titel: Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database
verfasst von: Takahisa Mikami, MD
Bobby Liaw, MD
Mizuho Asada, PhD
Takahiro Niimura, BS
Yoshito Zamami, PhD
Deborah Green-LaRoche, MD
Lori Pai, MD
Michael Levy, MD PhD
Suriya Jeyapalan, MD MPH
Publikationsdatum: 09.01.2021
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2021
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03687-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?

Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence

Surgery on giant meningiomas in very old patients entails frequent postoperative intracranial hemorrhages and atypical histopathology

Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma

5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas

Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma